Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3459MR)

This product GTTS-WQ3459MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3459MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3346MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ9914MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ11339MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ2696MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ4620MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ11965MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ12418MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ6034MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW